03:23 , Mar 1, 2019 |  BC Innovations  |  Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
01:17 , Feb 16, 2019 |  BC Extra  |  Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

In a week that had a pair of innovative Chinese companies raise early venture rounds and a Bay Area company debut its digital biomanufacturing platform, the biggest series A round went to Philadelphia gene therapy...
00:17 , Feb 16, 2019 |  BioCentury  |  Finance

Andera looks early for cancer immunotherapy

Andera Partners changed gears with an early investment in preclinical company Grey Wolf Therapeutics to diversify its cancer immunotherapy portfolio. Along with Canaan Partners, Andera backed a £10 million ($12.9 million) series A for Grey...
18:23 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
06:05 , Feb 11, 2019 |  BC Extra  |  Financial News

Andera, Canaan lead Grey Wolf £10M A round

Cancer immunotherapy company Grey Wolf Therapeutics closed the second tranche of its total £10 million ($12.9 million) series A round to fund development of its immuno-oncology therapies to increase tumor visibility. The round was led...
15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million on Nov. 13 in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1...
11:33 , Nov 13, 2018 |  BC Extra  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1 pioneer Lieping Chen...
17:25 , Sep 14, 2018 |  BC Week In Review  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
22:22 , Sep 11, 2018 |  BC Extra  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
18:31 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...